However, further studies are needed to determine the frequency of the occurrence of SGLT-2 inhibitor-related sarcopenia and whether SGLT-2 inhibitors cause diabetes-related sarcopenia, as clinical data are limited. This evidence concerns the gene SLC5A2 and sarcopenia.